One Health Biosensing
One Health Biosensing is a pre-revenue medical device company developing a needle-free continuous glucose monitor (FlexCGM) for people with Type 2 diabetes and metabolic conditions, using a micro-needle sensing platform and an AI-enabled mobile app.
- Company typePrivate
- Founded2024
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What One Health Biosensing does
One Health Biosensing is a privately held, pre-revenue medical device company founded in 2024 by Jeff Dachis, the founder of One Drop. The company is developing the FlexCGM, a next-generation intradermal continuous glucose monitor built on a micro-needle sensing platform developed over approximately ten years. The system combines a reusable battery pod and transmitter with a daily disposable sensor, engineered to deliver pain-free, needle-free glucose monitoring at the lowest per-day cost. An AI-enabled companion mobile app provides precision health guidance intended to drive action and improve outcomes even on non-wear days.
The product targets adults with Type 2 diabetes — explicitly the more than 90% of T2D patients who do not currently use a CGM due to cost and access barriers — as well as individuals with obesity and other metabolic conditions who could benefit from continuous glucose data for lifestyle management. The company plans to submit FlexCGM for FDA clearance in 2026; the device is currently investigational and not approved or cleared by the U.S. Food and Drug Administration.
One Health Biosensing operates a direct-to-consumer model with tiered monthly subscriptions (5, 7, or daily sensors per month) under the Recently Diagnosed, Regaining Control, and Ready for More plans, pairing durable hardware with recurring consumable revenue. Distribution is concentrated on the company's own website, with no third-party retail, pharmacy, or payer relationships disclosed. The company is based in New York, has 1-10 employees, has disclosed no external funding, and is currently founder-controlled.
One Health Biosensing firmographics
Firmographics- Name
- One Health Biosensing
- Legal name
- One Health Biosensing
- Website
- https://onehealthbiosensing.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- One Health Biosensing is a pre-revenue medical device company developing a needle-free continuous glucose monitor (FlexCGM) for people with Type 2 diabetes and metabolic conditions, using a micro-needle sensing platform and an AI-enabled mobile app.
- Ownership category
- akta.pro rank
One Health Biosensing industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
- akta.pro secondary industries
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where One Health Biosensing is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
One Health Biosensing business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Others
Revenue model
- CGM device and consumables (sensor) sales: The company sells a reusable battery pod/transmitter as durable hardware, combined with daily disposable sensors that are replaced regularly. Users select from tiered plans offering 5, 7, or daily sensors per month, implying a recurring consumables revenue model alongside durable hardware.
- Subscription/consumables recurring revenue: Customers subscribe to a monthly plan that determines how many sensors they receive per month. Plan tiers (Recently Diagnosed: 5 sensors/month; Regaining Control: 7 sensors/month; Ready for More: daily sensor all month) indicate a recurring consumable delivery model with tiered pricing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Recently Diagnosed: 5 sensors per month |
| Subscription | Monthly | Regaining Control: 7 sensors per month |
| Subscription | Monthly | Ready for More: Daily sensor all month long |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
One Health Biosensing product offering
Product offeringCore offering
One Health Biosensing develops and intends to sell the FlexCGM (One Health Biosensor), a next-generation intradermal continuous glucose monitor that uses a micro-needle sensing platform to read glucose without penetrating the skin. The system combines a reusable battery pod/transmitter with daily disposable sensors and is delivered through tiered monthly subscription plans alongside an AI-enabled companion mobile app that delivers precision health guidance.
Product overview
One Health Biosensing offers a single unified product ecosystem centered on its One Health Biosensor (FlexCGM) continuous glucose monitoring device and companion One Health App. The system integrates a reusable battery pod with daily disposable sensors to minimize cost while maximizing accessibility. The platform is powered by 10 years of development and 60+ billion data points, with AI-enabled precision guidance delivered through the app to improve health outcomes for people with Type 2 diabetes.
Differentiator
Problem solved
Functional benefit
Products and services
- One Health Biosensor (FlexCGM) Next-generation intradermal continuous glucose monitoring (CGM) device that uses a micro-needle sensing platform to read glucose without penetrating through the skin; pairs a reusable battery pod/transmitter with daily disposable sensors and is offered to individuals with Type 2 diabetes and metabolic conditions through tiered monthly subscription plans.
- One Health App AI-enabled companion mobile application that delivers precision health guidance informed by the FlexCGM biosensor and over 60 billion data points, providing actionable insights even on non-CGM days and supporting users across the Recently Diagnosed, Regaining Control, and Ready for More programs.
Quantifiable outcome
- Over 90% of people with Type 2 diabetes do not use a CGM despite clinical benefit, due to lack of access and affordability — representing the addressable unmet need
Companies that use One Health Biosensing
Customer profileSegments2 records
Ideal customer profiles2 records
One Health Biosensing technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
One Health Biosensing partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
One Health Biosensing competitors and assessment
Company assessmentBroad incumbents
- Roche Diabetes Care (Accu-Chek): Roche's Accu-Chek franchise includes traditional blood glucose meters and the newer Accu-Chek Smart CGM / Insight CGM offering. Comparable because Roche operates broadly in diabetes monitoring devices, though it is a diversified incumbent with legacy BGM stick business rather than a CGM-pure-play challenger like One Health Biosensing.
- Medtronic (Guardian / MiniMed): Medtronic sells the Guardian Connect CGM alongside its MiniMed insulin pump and AID systems as part of a broader diabetes franchise. Comparable because Medtronic operates in the same continuous glucose monitoring device category, though its offering is bundled into integrated insulin-delivery systems rather than positioned as a low-cost DTC product like FlexCGM.
Emerging players
- Levels Health: Levels Health is a DTC metabolic health subscription that pairs CGM hardware (currently Abbott Libre) with a software guidance layer for consumers without diabetes. Comparable because Levels uses the same DTC, subscription, app-led playbook that FlexCGM is built around, validating the consumer metabolic-health CGM market One Health Biosensing is entering.
- Signos: Signos combines a CGM sensor with an AI-driven app for weight loss and metabolic optimization, sold DTC to consumers. Comparable because Signos directly competes for the same non-T1D consumer CGM-plus-AI subscription wallet and demonstrates the demand for AI-guided glucose insights that FlexCGM's app layer is designed to deliver.
- Nutrisense: Nutrisense offers a DTC CGM-based program with personalized nutritionist coaching for people focused on metabolic health and weight management. Comparable because Nutrisense targets the same pre-diabetic / health-conscious consumer with bundled CGM plus app-driven guidance, mirroring One Health Biosensing's DTC subscription tier model.
Direct peers
- Nemaura Medical (SugarBEAT / Miboko): Nemaura is a small-cap CGM developer with a non-invasive / skin-patch continuous glucose sensor aimed at consumer and prediabetes use cases. Comparable because Nemaura targets the same non-insulin, mass-market metabolic health opportunity as One Health Biosensing and similarly positions around affordability and accessibility versus incumbents.
- Senseonics (Eversense): Senseonics makes the Eversense implantable CGM, the longest-duration sensor on the market. Comparable because Senseonics is a smaller, CGM-pure-play pursuing a differentiated, non-traditional sensing approach against Dexcom/Abbott, much like One Health Biosensing's novel intradermal micro-needle platform targets a different architecture than incumbent filament-based CGMs.
- Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the highest-volume consumer CGM globally and a direct competitor to FlexCGM in the same product category. Comparable because both offer factory-calibrated, app-connected wearable glucose sensors sold direct or via pharmacy to people with diabetes, and Abbott's OTC Lingo and Libre variants specifically target the non-insulin T2D market that One Health is pursuing.
- Dexcom: Dexcom is the leading pure-play continuous glucose monitor manufacturer (G6, G7), competing head-on with One Health Biosensing's FlexCGM in the CGM category. Comparable because both sell wearable glucose sensors with app-based guidance to people with diabetes, though Dexcom is currently dominant in Type 1 and insulin-using populations while One Health is targeting the broader T2D non-adopter pool.
Others
- Insulet (Omnipod): Insulet makes the Omnipod patch insulin pump, an adjacent wearable diabetes device category. Comparable as an adjacent diabetes wearable player that shares target customers (people with diabetes) and a wearable consumables revenue model, though Insulet is in insulin delivery rather than glucose sensing, making it ecosystem-relevant rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
One Health Biosensing social profiles
Digital presenceOne Health Biosensing financial estimates
Financial estimateRevenue estimate
Valuation estimate
One Health Biosensing leadership team
Management profileNumber of profiles
Profiles1 record
One Health Biosensing funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
One Health Biosensing M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about One Health Biosensing
What does One Health Biosensing do?
One Health Biosensing develops and intends to sell the FlexCGM (One Health Biosensor), a next-generation intradermal continuous glucose monitor that uses a micro-needle sensing platform to read glucose without penetrating the skin. The system combines a reusable battery pod/transmitter with daily disposable sensors and is delivered through tiered monthly subscription plans alongside an AI-enabled companion mobile app that delivers precision health guidance.
Is One Health Biosensing a public or private company?
One Health Biosensing is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was One Health Biosensing founded?
One Health Biosensing was founded in 2024. It employs 1 to 10 people.
Where is One Health Biosensing based?
One Health Biosensing is headquartered in New York, United States, in the North America region.
How does One Health Biosensing make money?
Two revenue lines are on record. CGM device and consumables (sensor) sales are the primary driver. The others are subscription/consumables recurring revenue.
Who are One Health Biosensing's main competitors?
Broad incumbents on record are Roche Diabetes Care (Accu-Chek) and Medtronic (Guardian / MiniMed). Emerging players are Levels Health, Signos and Nutrisense. Direct peers are Nemaura Medical (SugarBEAT / Miboko), Senseonics (Eversense), Abbott (FreeStyle Libre) and Dexcom. Insulet (Omnipod) is listed as an others.
Does One Health Biosensing have an API?
No public API is recorded for One Health Biosensing.
What industry is One Health Biosensing in?
One Health Biosensing's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 334510 and its SIC code is 3845.